Dermira, Inc. (NASDAQ:DERM)‘s stock had its “buy” rating restated by equities researchers at Mizuho in a research report issued to clients and investors on Thursday. They presently have a $43.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $40.00. Mizuho’s target price would suggest a potential upside of 69.09% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. Zacks Investment Research downgraded Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Needham & Company LLC reiterated a “buy” rating and set a $46.00 price target on shares of Dermira in a report on Tuesday, July 18th. Evercore ISI initiated coverage on Dermira in a report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target for the company. Cantor Fitzgerald initiated coverage on Dermira in a report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price target for the company. Finally, BidaskClub downgraded Dermira from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $44.40.

Dermira (NASDAQ DERM) traded up 5.08% during midday trading on Thursday, reaching $25.43. 644,576 shares of the company were exchanged. The firm’s market cap is $1.06 billion. Dermira has a one year low of $21.35 and a one year high of $38.75. The firm’s 50-day moving average is $25.07 and its 200-day moving average is $29.92.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by $0.04. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1 million. On average, equities analysts expect that Dermira will post ($4.17) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/07/dermira-inc-derm-earns-buy-rating-from-mizuho.html.

In other Dermira news, Director Fred B. Craves acquired 30,000 shares of Dermira stock in a transaction on Monday, August 14th. The stock was purchased at an average price of $23.03 per share, for a total transaction of $690,900.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $29.06, for a total value of $145,300.00. The disclosure for this sale can be found here. Insiders sold a total of 11,700 shares of company stock valued at $337,537 in the last 90 days. Corporate insiders own 13.30% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. AXA grew its stake in shares of Dermira by 10.9% during the 1st quarter. AXA now owns 212,254 shares of the biopharmaceutical company’s stock worth $7,240,000 after acquiring an additional 20,795 shares during the period. Vanguard Group Inc. grew its stake in shares of Dermira by 20.7% during the 1st quarter. Vanguard Group Inc. now owns 1,272,700 shares of the biopharmaceutical company’s stock worth $43,412,000 after acquiring an additional 217,943 shares during the period. American International Group Inc. grew its stake in shares of Dermira by 23.4% during the 1st quarter. American International Group Inc. now owns 14,900 shares of the biopharmaceutical company’s stock worth $508,000 after acquiring an additional 2,829 shares during the period. Geode Capital Management LLC grew its stake in shares of Dermira by 27.6% during the 1st quarter. Geode Capital Management LLC now owns 252,345 shares of the biopharmaceutical company’s stock worth $8,607,000 after acquiring an additional 54,646 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Dermira during the 1st quarter worth $1,023,000. Hedge funds and other institutional investors own 97.56% of the company’s stock.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.